Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In the run-in phase:~  * Standard surgery for fracture of the upper third of the femur, including femoral head and neck~* In the double-blind phase following the run-in phase:~  * Completion of the run-in phase without permanent treatment discontinuation~Exclusion Criteria:~* Any major orthopedic surgery within 3 months prior to enrolment;~* Deep vein thrombosis or pulmonary embolism within the last 12 months, or known post-phlebitic syndrome;~* High risk of bleeding;~* Known hypersensitivity to heparins;~* Any contraindication to the performance of venography;~* End stage renal disease or patient on dialysis~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semuloparin extension treatment (Type: EXPERIMENTAL): Extension treatment with Semuloparin sodium 20 mg (10 mg if SRI) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days.
- Placebo extension treatment (Type: PLACEBO_COMPARATOR): Extension treatment with placebo (for Semuloparin sodium) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).